Trial Outcomes & Findings for RTA 408 Capsules in Patients With Melanoma - REVEAL (NCT NCT02259231)

NCT ID: NCT02259231

Last Updated: 2025-06-04

Results Overview

Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 41 participants
• Primary outcome timeframe: From enrollment up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab
• Results posted on: 2025-06-04

Participant Flow

Participant milestones

Measure	Omaveloxolone 5 mg & Ipilimumab Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Overall Study STARTED	6	6	6	6	6	6	5
Overall Study COMPLETED	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	6	6	6	6	6	6	5

Reasons for withdrawal

Measure	Omaveloxolone 5 mg & Ipilimumab Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Overall Study Adverse Event	1	1	2	0	0	0	0
Overall Study Progressive Disease	4	5	4	5	4	5	4
Overall Study Sponsor termination of study	1	0	0	1	2	1	1

Baseline Characteristics

RTA 408 Capsules in Patients With Melanoma - REVEAL

Baseline characteristics by cohort

Measure	Omaveloxolone 5 mg & Ipilimumab n=6 Participants Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab n=6 Participants Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab n=6 Participants Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab n=6 Participants Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab n=6 Participants Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab n=6 Participants Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab n=5 Participants Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Total n=41 Participants Total of all reporting groups
Age, Continuous	59.17 years STANDARD_DEVIATION 18.713 • n=5 Participants	53.5 years STANDARD_DEVIATION 8.24 • n=7 Participants	68.33 years STANDARD_DEVIATION 12.42 • n=5 Participants	51.67 years STANDARD_DEVIATION 11.29 • n=4 Participants	60.5 years STANDARD_DEVIATION 13.882 • n=21 Participants	65 years STANDARD_DEVIATION 7.321 • n=10 Participants	65 years STANDARD_DEVIATION 5.958 • n=115 Participants	60.3 years STANDARD_DEVIATION 12.49 • n=24 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	4 Participants n=21 Participants	4 Participants n=10 Participants	1 Participants n=115 Participants	17 Participants n=24 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	4 Participants n=115 Participants	24 Participants n=24 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	2 Participants n=24 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=5 Participants	6 Participants n=7 Participants	5 Participants n=5 Participants	5 Participants n=4 Participants	6 Participants n=21 Participants	6 Participants n=10 Participants	5 Participants n=115 Participants	39 Participants n=24 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) White	6 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	6 Participants n=10 Participants	5 Participants n=115 Participants	41 Participants n=24 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants

PRIMARY outcome

Timeframe: From enrollment up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab

Population: Evaluable analysis set (EAS) is defined as all enrolled patients having received at least two weeks of study drug before disease progression and excludes patients who discontinued from study for reasons other than an adverse event prior to first tumor restaging.

Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR.

Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.

Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.

Outcome measures

Measure	Omaveloxolone 5 mg & Ipilimumab n=6 Participants Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab n=3 Participants Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab n=6 Participants Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab n=4 Participants Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab n=5 Participants Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab n=5 Participants Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab n=5 Participants Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria Best Overall Responses	6 Participants	0 Participants	5 Participants	2 Participants	3 Participants	3 Participants	4 Participants
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria Progressive Disease	3 Participants	0 Participants	3 Participants	0 Participants	1 Participants	3 Participants	2 Participants
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria Stable Disease	1 Participants	0 Participants	1 Participants	1 Participants	1 Participants	1 Participants	1 Participants
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria Partial Response	3 Participants	0 Participants	0 Participants	2 Participants	2 Participants	0 Participants	2 Participants
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria Complete Response	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants

Adverse Events

Omaveloxolone 5 mg & Ipilimumab

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

Omaveloxolone 10 mg & Ipilimumab

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

Omaveloxolone 5 mg & Nivolumab

Serious events: 1 serious events

Other events: 6 other events

Deaths: 1 deaths

Omaveloxolone 10 mg & Nivolumab

Serious events: 3 serious events

Other events: 6 other events

Deaths: 1 deaths

Omaveloxolone 20 mg & Nivolumab

Serious events: 2 serious events

Other events: 6 other events

Deaths: 2 deaths

Omaveloxolone 100 mg & Nivolumab

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

Omaveloxolone 150 mg & Nivolumab

Serious events: 2 serious events

Other events: 5 other events

Deaths: 1 deaths

Serious adverse events

Measure	Omaveloxolone 5 mg & Ipilimumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab n=5 participants at risk Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Infections and infestations Lung Infection	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Soft tissue infection	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Clostridial infection	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Colitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Abdominal pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Oesophageal disorder	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Cerebral thrombosis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Hemiparesis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Transient ischaemic attack	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Disease progression	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Pyrexia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Blood and lymphatic system disorders Anaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood creatinine phosphokinase increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Troponin increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Dehydration	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Hypotension	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.

Other adverse events

Measure	Omaveloxolone 5 mg & Ipilimumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg	Omaveloxolone 10 mg & Ipilimumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10. Ipilimumab (3 mg/kg): Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 5 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Omaveloxolone Capsules (2.5 mg/capsule): Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg	Omaveloxolone 10 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 20 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (10 mg/capsule): Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 100 mg & Nivolumab n=6 participants at risk Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label	Omaveloxolone 150 mg & Nivolumab n=5 participants at risk Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 169 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated. Nivolumab (240 mg): Sterile solution containing nivolumab to be delivered intravenously at 240 mg Omaveloxolone Capsules (50 mg/capsule): Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Blood and lymphatic system disorders Anaemia	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Blood and lymphatic system disorders Bone marrow failure	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Blood and lymphatic system disorders Leukopenia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Cardiac disorders Cardiac failure	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Cardiac disorders Palpitations	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Cardiac disorders Sinus bradycardia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Cardiac disorders Sinus tachycardia	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Congenital, familial and genetic disorders Multiple lentigines syndrome	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Ear and labyrinth disorders Ear pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Ear and labyrinth disorders Vertigo	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Endocrine disorders Adrenal insufficiency	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Endocrine disorders Hypophysitis	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Endocrine disorders Hypothyroidism	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Conjunctivitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Dry eye	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Eye disorder	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Eye irritation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Mydriasis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Photophobia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Vision blurred	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Eye disorders Vitreous floaters	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Abdominal distension	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Abdominal pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Abdominal pain upper	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Ascites	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Colitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Constipation	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Diarrhoea	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Dry mouth	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Dyspepsia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Dysphagia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Faecal incontinence	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Faeces discoloured	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Flatulence	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Gastric ulcer	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Gastrooesophageal reflux disease	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Haemorrhoids	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Hiatus hernia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Melaena	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Mucous stools	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Nausea	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Oesophageal disorder	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Oral disorder	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Rectal haemorrhage	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Toothache	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Gastrointestinal disorders Vomiting	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Asthenia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Chills	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Early satiety	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Face oedema	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Fatigue	83.3% 5/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	83.3% 5/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	83.3% 5/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	100.0% 6/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	60.0% 3/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Gait disturbance	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Influenza like illness	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Localised oedema	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Malaise	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Mucosal inflammation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Nodule	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Non-cardiac chest pain	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Oedema peripheral	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Pain	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
General disorders Pyrexia	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Immune system disorders Hypersensitivity	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Clostridial infection	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Gastroenteritis	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Laryngitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Nasopharyngitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Oral candidiasis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Pneumonia	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Sinusitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Skin infection	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Soft tissue infection	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Upper respiratory tract infection	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Urinary tract infection	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Infections and infestations Wound infection	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Contusion	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Excoriation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Fall	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Infusion related reaction	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Laceration	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Open wound	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Stress fracture	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Injury, poisoning and procedural complications Wound complication	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Alanine aminotransferase increased	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Aspartate aminotransferase increased	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Biopsy site unspecified abnormal	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood alkaline phosphatase increased	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood bilirubin increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood cholesterol increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood corticotrophin decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood creatine phosphokinase increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood creatinine increased	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood potassium increased	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood testosterone decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood thyroid stimulating hormone decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood triglycerides increased	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Blood uric acid increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Brain natriuretic peptide increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Cardiac murmur	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Electrocardiogram QT prolonged	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Gamma-glutamyltransferase increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Haemoglobin decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Heart rate increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations International normalised ratio increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Low density lipoprotein increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Lymphocyte count decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Lymphocyte count increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Oesophagogastroduodenoscopy	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Platelet count decreased	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Serum ferritin decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Troponin increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Very low density lipoprotein increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Weight decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations Weight increased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Investigations White blood cell count decreased	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Decreased appetite	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Dehydration	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hyperglycaemia	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hyperkalaemia	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypomagnesaemia	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Metabolism and nutrition disorders Malnutrition	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Back pain	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Groin pain	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Muscle twitching	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Temporomandibular joint syndrome	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Tendonitis	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Musculoskeletal and connective tissue disorders Tenosynovitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign vaginal neoplasm	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour associated fever	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Cognitive disorder	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Disturbance in attention	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Dizziness	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Dysgeusia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Headache	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Hemiparesis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Memory impairment	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Neuropathy peripheral	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Paraesthesia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Sinus headache	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Speech disorder developmental	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders Tremor	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Nervous system disorders VIIth nerve paralysis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Psychiatric disorders Confusional state	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Psychiatric disorders Decreased activity	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Psychiatric disorders Insomnia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Haematuria	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Polyuria	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Proteinuria	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Renal failure	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Renal failure acute	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Urinary hesitation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Renal and urinary disorders Urinary incontinence	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Reproductive system and breast disorders Breast pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Reproductive system and breast disorders Pelvic pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Cough	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Dyspnoea	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	40.0% 2/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Laryngeal inflammation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	60.0% 3/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Organising pneumonia	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Orthopnoea	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Pneumothorax	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Actinic keratosis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Dry skin	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Pruritus	66.7% 4/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	50.0% 3/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Pruritus generalised	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Rash	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Rash erythematous	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Rash generalised	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Rash macular	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	33.3% 2/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Skin hypopigmentation	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Skin induration	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Skin lesion	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Skin mass	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Systemic lupus erythematosus rash	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Skin and subcutaneous tissue disorders Vitiligo	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Surgical and medical procedures Micrographic skin surgery	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Surgical and medical procedures Tooth extraction	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Haematoma	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Haemorrhage	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Hot flush	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Hypertension	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	20.0% 1/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Hypotension	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Jugular vein thrombosis	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.
Vascular disorders Lymphoedema	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	16.7% 1/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/6 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.	0.00% 0/5 • Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab. Collection of adverse event information was done based on regular investigator assessment during patients visits.

Additional Information

US Biogen Clinical Trial Center

Biogen

Phone: 866-633-4636

Email: clinicaltrials@biogen.com

Results disclosure agreements

• Principal investigator is a sponsor employee Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.
• Publication restrictions are in place

Restriction type: OTHER